Exclusive: After Turning Point success, oncology vets in-license first asset for Avenzo Therapeutics
Athena Countouriotis and her former colleagues at Turning Point Therapeutics have in-licensed their first oncology asset at their next venture, Avenzo Therapeutics, which is on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.